Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows

v3.21.2
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Cash flows from operating activities    
Net loss $ (15,883) $ (21,751)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 110 126
Stock-based compensation expense 2,383 1,937
Change in fair value of warrant liabilities (17,210) (3,800)
Issuance costs allocated to warrants   2,175
Net amortization of premium on marketable securities 503 161
Changes in operating assets and liabilities:    
(Increase) decrease in prepaid expenses and other current and non-current assets (6,260) 720
Increase (decrease) in accounts payable, accrued liabilities and other liabilities 3,800 (5,240)
Net cash used in operating activities (32,557) (25,672)
Cash flows from investing activities    
Purchases of marketable securities (47,644) (47,555)
Proceeds from sales and maturities of marketable securities 31,034 15,303
Net cash used in investing activities (16,610) (32,252)
Cash flows from financing activities    
Proceeds from issuance of securities 57,500 55,500
Payment of financing costs of securities sold (3,703) (3,637)
Proceeds from the exercise of warrants 110 29
Net cash provided by financing activities 53,907 51,892
Net increase (decrease) in cash and cash equivalents 4,740 (6,032)
Cash and cash equivalents at beginning of period 15,485 24,184
Cash and cash equivalents at end of period $ 20,225 18,152
Supplemental disclosures of cash flow information:    
Issuance of warrants to purchase common stock   $ 31,392